Business Model Breakdown
How Can Fite Biopharma Ltd Makes Money
CANF
Market Cap
$7M
Annual Revenue
$410,000
Profit Margin
0.0%
Employees
5
The Short Version
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company focused on developing small molecule drugs that modulate the A3 adenosine receptor for the treatment of inflammatory diseases, cancer, and liver diseases. Currently, it generates very limited revenue, primarily through early-stage licensing agreements or niche commercialization (e.g., animal health via Vetbiolix). Its core business model relies on the successful development, regulatory approval, and eventual commercialization or licensing of its proprietary drug candidates, specifically Namodenoson and Piclidenoson, to generate significant future revenues through product sales or milestone and royalty payments from partners.
Where the Revenue Comes From
Licensing/Royalty Revenue (~100% of reported revenue, currently $0.41M for FY2025).
Who buys: Primarily other pharmaceutical/biotech companies for licensing, or potentially animal health distributors (via Vetbiolix). End-users would eventually be patients through prescribers if drugs are approved.
Why It Works (Competitive Advantages)
- ✔Proprietary A3 adenosine receptor modulation technology for lead candidates.
- ✔Early-stage clinical data in high-unmet-need cancer indications (pancreatic cancer, HCC).
Economic Moat: None (Intangible Assets/IP)
What Our Analysis Says
DVR Score as of April 8, 2026
Can-Fite BioPharma Ltd. remains an extremely high-risk, deeply speculative investment, with a very low probability of achieving 10x growth within 3-5 years. While FY2025 financials show declining revenue and worsening net loss, recent material positive catalysts warrant a slight score increase. These include an improved short-term cash position (+$4.3M in March 2026, totaling ~$12.84M), significant clinical progress for Namodenoson in pancreatic cancer (meeting safety endpoint, efficacy signals), and advancement of Piclidenoson in a Phase 2 dog study. These developments address previous concerns about pipeline stagnation and liquidity. However, fundamental risks persist: heavy cash burn, ongoing dilution, and the exceptionally long, costly, and uncertain path to market for any biotech drug. The competitive landscape in cancer and liver diseases is fierce, and commercialization capabilities are non-existent. The investment opportunity is purely speculative, hinged on major future clinical successes and large partnerships.